文献速递肝病消化道肿瘤与早癌

白种人慢性乙型肝炎患者接受恩替卡韦或替诺福韦治疗首个5年后肝细胞癌风险下降

The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B.
PubMed 文献 · Hepatology · 2017-10-11

这项欧洲10中心队列研究纳入1,951例基线无肝细胞癌的成年白种人慢性乙型肝炎患者,接受恩替卡韦或替诺福韦治疗至少1年。首个5年内肝细胞癌年发病率为1.22%,5年后降至0.73%(P=0.050);肝硬化患者从3.22%降至1.57%(P=0.039),无肝硬化患者无显著差异。

要点

  • 首个5年后肝细胞癌年发病率0.73%,低于前5年的1.22%(P=0.050)。
  • 肝硬化患者肝细胞癌年发病率从3.22%降至1.57%(P=0.039),无肝硬化者无显著差异。
  • 5年后发生的肝细胞癌均见于启动恩替卡韦或替诺福韦治疗时年龄超过50岁者。

核心结论

  • 白种人慢性乙型肝炎患者接受恩替卡韦或替诺福韦治疗超过5年后肝细胞癌风险下降,尤其在代偿期肝硬化患者中。
  • 年龄较大(尤其≥50岁)、血小板较低及第5年肝脏硬度≥12 kPa是晚期肝细胞癌发生的主要危险因素。

研究设计与样本

  • 欧洲10中心队列研究,纳入1,951例基线无肝细胞癌、接受恩替卡韦或替诺福韦治疗≥1年的成年白种人慢性乙型肝炎患者。
  • 其中1,205例(62%)在治疗首个5年内无肝细胞癌的患者被随访5-10年(中位6.8年)。

主要发现

  • 首个5年内诊断肝细胞癌101/1,951例(5.2%),5-10年内诊断17/1,205例(1.4%)。
  • 肝细胞癌年发病率在首个5年内为1.22%,5年后为0.73%(P=0.050)。
  • 无肝硬化患者首个5年内与5年后肝细胞癌年发病率无显著差异(0.49% vs 0.47%,P=0.931)。
  • 肝硬化患者肝细胞癌年发病率从首个5年内的3.22%降至5年后的1.57%(P=0.039)。
  • 多变量分析显示,年龄较大、基线及第5年血小板较低、第5年肝脏硬度≥12 kPa与5年后肝细胞癌发生更频繁独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Whether there is a change of hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent nucleos(t)ide analogues is currently unclear. We therefore assessed the HCC incidence beyond year 5 of entecavir/tenofovir (ETV/TDF) therapy and tried to determine possible factors associated with late HCC occurrence. This European, 10-center, cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who received ETV/TDF for ≥1 year. Of them, 1,205 (62%) patients without HCC within the first 5 years of therapy have been followed for 5-10 (median, 6.8) years. HCCs have been diagnosed in 101/1,951 (5.2%) patients within the first 5 years and 17/1,205 (1.4%) patients within 5-10 years. The yearly HCC incidence rate was 1.22% within and 0.73% after the first 5 years (P = 0.050). The yearly HCC incidence rate did not differ within and after the first 5 years in patients without cirrhosis (0.49% versus 0.47%, P = 0.931), but it significantly declined in patients with cirrhosis (3.22% versus 1.57%, P = 0.039). All HCCs beyond year 5 developed in patients older than 50 years at ETV/TDF onset. Older age, lower platelets at baseline and year 5, and liver stiffness ≥12 kPa at year 5 were independently associated with more frequent HCC development beyond year 5 in multivariable analysis. No patient with low Platelets, Age, Gender-Hepatitis B score at baseline or year 5 developed HCC. CONCLUSION: The HCC risk decreases beyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with compensated cirrhosis; older age (especially ≥50 years), lower platelets, and liver stiffness ≥12 kPa at year 5 represent the main risk factors for late HCC development. (Hepatology 2017;66:1444-1453).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017. PMID: 28622419. doi:10.1002/hep.29320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。